[ransomnote]

Ymani Cricket wrote:

@TruthSeeker8487
18h

----> For real. "Starting to truly understand why the French Revolution was so brutal."

https://pubmed.ncbi.nlm.nih.gov/34466270/

 

I see that it has been posted to FR twice but just excerpts because it's taken from 3rd party sources.

 

Article is FREE (no copyright) at the link:

 

Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19 (nih.gov)

 

and the full article is posted to an old Festival on FR

 

Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19 (freerepublic.com)

 

[Ymani Cricket]

@Muse2Pharaoh
/g/The_Donald
@Takeoutds I love that the meme mentions the AMA. Here's another fun fact from the AMA's own encyclopedia: #Menticide #SubmissionAgenda

[Ymani Cricket]

----> https://pubmed.ncbi.nlm.nih.gov/32908214/

Abstract

Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials. Here, we describe key ADE mechanisms and discuss mitigation strategies for SARS-CoV-2 vaccines and therapies in development. We also outline recently published data to evaluate the risks and opportunities for antibody-based protection against SARS-CoV-2.

[WildHighlander57]

ransomnote wrote:

“
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383101/
“

ThankQs, MqD!

The punchline:

“Conclusion

We believe that the evidence to date supports the worldwide extension of IVM treatments for COVID-19, complementary to immunizations. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, as reviewed [8], possibly yielding full efficacy against emerging viral mutant strains. IVM has been safely used in 3.7 billion doses since 1987, well tolerated even at much greater than standard doses [34,35] and used without serious AEs in the three high-dose COVID-19 treatment studies noted above [34,36,37]. In the current international emergency of COVID-19, with mutant viral strains, vaccination refusals and potentially waning immunities over months presenting new challenges, IVM can be an effective component of the mix of therapeutics deployed against this pandemic.”

[Melian]

Ping to 961